Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Beacon Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$182,520

40 payments

Through program year 2025, Beacon Clinical Research is reported as receiving $182,520 in research payments, across 40 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $10,100 6
2024 Research $18,875 4
2023 Research $24,229 7
2022 Research $16,135 7
2021 Research $17,861 2
2020 Research $26,824 9
2019 Research $68,496 5

Breakdown

Who paid Research payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $128,702 8 payments
  2. AbbVie, Inc. $42,886 21 payments
  3. OPKO Pharmaceuticals, LLC $7,350 2 payments
  4. Novartis Pharmaceuticals Corporation $2,162 1 payment
  5. Endo Pharmaceuticals Inc. $1,000 1 payment
  6. Pfizer Inc. $421 7 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis $52,460 1 payment
  2. Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis $46,912 4 payments
  3. A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) $36,108 18 payments
  4. A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis $22,806 2 payments
  5. Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) $7,350 2 payments
  6. Phase III Long Term Roll Over Psoriasis $6,525 1 payment
  7. M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) $4,950 2 payments
  8. A 52 Week Multicenter Randomized Double Blind Study of Secukinumab 300 MG to Demonstrate Efficacy As Assessed By Psoriasis Area and Severity Index and Investigators Global Assessment After 12 Weeks of Treatment, Compared to Ustekinumab and to Assess Long $2,162 1 payment
  9. A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) $1,828 1 payment
  10. A Phase 3B, Open-Label, Long-Term Study to Evaluate the Safety and Temporal Pattern of Response of En3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy $1,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record